
SELLAS Life Sciences plunged about 23% premarket after pricing a $150 million underwritten public offering. The dilutive raise lands just days after the stock ran up on Phase 3 leukemia data, and the offering size is large relative to the company's market value. Sellers are pricing in the dilution, not the pipeline.